An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus (VIVID)

B5K-MC-IBHD -

The main purpose of this study is to evaluate the safety and efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus

Trial Summary

Age Range
18 - 85 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Insulin
Could I receive a Placebo?
No
Enrollment Goal
420
Trial Dates
Oct 20, 2015 - May 9, 2017
How long will I be in the trial?
Your participation could last up to 26 weeks and include 10 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.